On Wednesday, Following U.S. Stocks were among the “Top Gainers”: Magnum Hunter Resources, (NYSE:MHR), Supernus Pharmaceuticals, (NASDAQ:SUPN), Celldex Therapeutics, (NASDAQ:CLDX), Lion Biotechnologies, (NASDAQ:LBIO)

Magnum Hunter Resources Corp. (NYSE:MHR), with shares inclined 3.49%, closed at $2.37.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), with shares jumped 10.78%, settled at $11.

Celldex Therapeutics, Inc. (NASDAQ:CLDX), with shares climbed 3.66%, and closed at $29.45.

Lion Biotechnologies, (NASDAQ:LBIO), surged 10.16%, and closed at $11.28, hitting new 52-week high of $12.

Latest NEWS regarding these Stocks are depicted underneath:

Magnum Hunter Resources Corp. (NYSE:MHR)

Formerly on March 4, Magnum Hunter Resources Corp. (MHR), declared that the Corporation has designated Charlie Gibson as Vice President of Reservoir Engineering effective March 2, 2015. Mr. Gibson, age 56, will report to Gary C. Evans, Chairman & CEO of Magnum Hunter.

Mr. Gibson brings more than 30 years of engineering experience, counting operations, reservoir and reserve reporting, primarily within growth oriented oil and natural gas companies. Preceding to joining Magnum Hunter, Mr. Gibson served as Senior Vice President of Production Operations at Denbury Resources, Inc. (“Denbury”) since June 2014. During his twelve year tenure at Denbury, he held many managerial positions counting Senior Vice President of Planning, Technology and Business Development, Vice President of its West Region and Vice President of Reservoir Engineering and Geology. Mr. Gibson was a key participant in Denbury’s noteworthybusiness decisions. He was also involved in its analysis of potential attainments and integral to its reserve engineering process. Preceding to joining Denbury, Mr. Gibson served in various reservoir and engineering roles at Coho Resources and ORYX Energy. Mr. Gibson earned a Bachelor of Science in Petroleum Engineering degree from Louisiana State University.

Magnum Hunter Resources Corporation, an independent oil and gas corporation, explores for, exploits, attains, develops, and produces crude oil, natural gas, and natural gas liquid resources in the United States.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical corporation focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, stated financial results for the fourth quarter and full year 2014 and associated corporation developments.

Business Update:

Fourth quarter prescriptions, as stated by Symphony for Trokendi XR(R) and Oxtellar XR(R), totaled 70,739, increasing by 12,963, or 22%, as contrast to third quarter 2014. Trokendi XR prescriptions for the fourth quarter totaled 50,583, a 28% raise over the 39,524 prescriptions for the third quarter. Oxtellar XR prescriptions for the fourth quarter totaled 20,156, a 10% raise over the 18,252 prescriptions for the third quarter.

Managed care coverage continues to be strong for both products. Oxtellar XR now has 180.2 million lives covered and Trokendi XR has 174.0 million lives covered. Roughly 89% of Trokendi XR and 90% of Oxtellar XR national claims are approved by payors.

“During our November earnings call, we reiterated that the Corporation would become cash flow positive by the end of the fourth quarter. Not only was the Corporation cash flow positive for the month of December, but it was also significantly cash flow positive for the entire fourth quarter. In addition, net product proceed of about $30 million for the fourth quarter substantially exceeded our guidance of $24 million to $26 million. We are extremely proud of these accomplishments and our employees’ commitment to delivering on our promises,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.

“We look forward to another strong year in 2015, as we continue to build on the success of our product launches and growing prescription base,” said Mr. Khattar.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical corporation, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (CLDX), declared that the Corporation presented a corporate overview at the Cowen and Corporation 35th Annual Health Care Conference on Wednesday, March 4, at the Boston Marriott Copley Place Hotel in Boston, MA.

Celldex Therapeutics, Inc., a biopharmaceutical corporation, develops, manufactures, and commercializes novel therapeutics for human health care in the United States.

Lion Biotechnologies, Inc. (NASDAQ:LBIO)

Lion Biotechnologies, Inc. (LBIO), a biotechnology corporation that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), declared the closing of its underwritten public offering of 9,200,000 shares of its ordinary stock at $8.00 per share, counting 1,200,000 shares sold following the exercise in full of the underwriters’ option to purchase additional shares, resulting in gross proceeds from the offering of $73.6 million, before deducting underwriting discounts and commissions and offering expenses payable by Lion.

Lion intends to use the net proceeds of the offering for the development of its product candidates, counting its planned Phase 2 clinical trial for metastatic melanoma, and for other general corporate and working capital purposes.

Jefferies LLC, Cowen and Corporation, LLC and Piper Jaffray & Co. acted as the joint book-running managers of the offering, and Roth Capital Partners, LLC acted as co-manager.

Lion Biotechnologies, Inc., a development stage biotechnology corporation, develops T-cells and engineered T-cells for the treatment of various cancers. The corporation’s lead product candidate comprises a ready-to-infuse autologous T-cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with stage IV metastatic melanoma.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.